Transient Receptor Potential Type Vanilloid 1 Suppresses Skin Carcinogenesis

Overview

Journal Cancer Res

Specialty Oncology

Date 2009 Jan 22

PMID 19155296

Citations 38

Authors

Ann M Bode

Yong-Yeon Cho

Duo Zheng

Feng Zhu

Marna E Ericson

Wei-Ya Ma

Ke Yao

Zigang Dong

Affiliations

Soon will be listed here.

Abstract

Blockade of the transient receptor potential channel vanilloid subfamily 1 (TRPV1) is suggested as a therapeutic approach to pain relief. However, TRPV1 is a widely expressed protein whose function might be critical in various nonneuronal physiologic conditions. The epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase that is overexpressed in many human epithelial cancers and is a potential target for anticancer drugs. Here, we show that TRPV1 interacts with EGFR, leading to EGFR degradation. Notably, the absence of TRPV1 in mice results in a striking increase in skin carcinogenesis. The TRPV1 is the first membrane receptor shown to have a tumor-suppressing effect associated with the down-regulation of another membrane receptor. The data suggest that, although a great deal of interest has focused on TRPV1 as a target for pain relief, the chronic blockade of this pain receptor might increase the risk for cancer development.

Citing Articles

SUMOylation-induced membrane localization of TRPV1 suppresses proliferation and migration in gastric cancer cells.

Yang Y, Gu X, Weng W, Cheng J, Huang O, Pan S Cell Commun Signal. 2024; 22(1):465.

PMID: 39350261 PMC: 11441086. DOI: 10.1186/s12964-024-01850-0.

A journey from molecule to physiology and tools for drug discovery targeting the transient receptor potential vanilloid type 1 (TRPV1) channel.

Amaya-Rodriguez C, Carvajal-Zamorano K, Bustos D, Alegria-Arcos M, Castillo K Front Pharmacol. 2024; 14:1251061.

PMID: 38328578 PMC: 10847257. DOI: 10.3389/fphar.2023.1251061.

Nanoparticle-mediated TRPV1 channel blockade amplifies cancer thermo-immunotherapy via heat shock factor 1 modulation.

Li T, Jiang S, Zhang Y, Luo J, Li M, Ke H Nat Commun. 2023; 14(1):2498.

PMID: 37120615 PMC: 10148815. DOI: 10.1038/s41467-023-38128-x.

Anoctamins and Calcium Signalling: An Obstacle to EGFR Targeted Therapy in Glioblastoma?.

Dewdney B, Ursich L, Fletcher E, Johns T Cancers (Basel). 2022; 14(23).

PMID: 36497413 PMC: 9740065. DOI: 10.3390/cancers14235932.

The Cytotoxic Effects of Cannabidiol and Cannabigerol on Glioblastoma Stem Cells May Mostly Involve GPR55 and TRPV1 Signalling.

Lah T, Majc B, Novak M, Susnik A, Breznik B, Porcnik A Cancers (Basel). 2022; 14(23).

PMID: 36497400 PMC: 9738061. DOI: 10.3390/cancers14235918.

References

Haglund K, Sigismund S, Polo S, Szymkiewicz I, Di Fiore P, Dikic I . Multiple monoubiquitination of RTKs is sufficient for their endocytosis and degradation. Nat Cell Biol. 2003; 5(5):461-6. DOI: 10.1038/ncb983. View

Sanchez M, Sanchez A, Collado B, Malagarie-Cazenave S, Olea N, Carmena M . Expression of the transient receptor potential vanilloid 1 (TRPV1) in LNCaP and PC-3 prostate cancer cells and in human prostate tissue. Eur J Pharmacol. 2005; 515(1-3):20-7. DOI: 10.1016/j.ejphar.2005.04.010. View

Vriens J, Janssens A, Prenen J, Nilius B, Wondergem R . TRPV channels and modulation by hepatocyte growth factor/scatter factor in human hepatoblastoma (HepG2) cells. Cell Calcium. 2004; 36(1):19-28. DOI: 10.1016/j.ceca.2003.11.006. View

Schwarz E, Wolfs M, Tonner S, Wenning A, Quintana A, Griesemer D . TRP channels in lymphocytes. Handb Exp Pharmacol. 2007; (179):445-56. DOI: 10.1007/978-3-540-34891-7_26. View

Kim S, Lee S, Yun S, Kim J, Park J, Jeong H . Expression of vanilloid receptor 1 in cultured fibroblast. Exp Dermatol. 2006; 15(5):362-7. DOI: 10.1111/j.0906-6705.2006.00418.x. View

Toth B, Gannett P . Carcinogenicity of lifelong administration of capsaicin of hot pepper in mice. In Vivo. 1992; 6(1):59-63. View

Peschard P, Park M . Escape from Cbl-mediated downregulation: a recurrent theme for oncogenic deregulation of receptor tyrosine kinases. Cancer Cell. 2003; 3(6):519-23. DOI: 10.1016/s1535-6108(03)00136-3. View

Li W, Lee Y, Kim J, Kang S, Kim S, Kim K . Transient receptor potential vanilloid-1 mediates heat-shock-induced matrix metalloproteinase-1 expression in human epidermal keratinocytes. J Invest Dermatol. 2007; 127(10):2328-35. DOI: 10.1038/sj.jid.5700880. View

Eglen R, Hunter J, Dray A . Ions in the fire: recent ion-channel research and approaches to pain therapy. Trends Pharmacol Sci. 1999; 20(8):337-42. DOI: 10.1016/s0165-6147(99)01372-3. View

10.

Caterina M . Transient receptor potential ion channels as participants in thermosensation and thermoregulation. Am J Physiol Regul Integr Comp Physiol. 2006; 292(1):R64-76. DOI: 10.1152/ajpregu.00446.2006. View

11.

Ferby I, Reschke M, Kudlacek O, Knyazev P, Pante G, Amann K . Mig6 is a negative regulator of EGF receptor-mediated skin morphogenesis and tumor formation. Nat Med. 2006; 12(5):568-73. DOI: 10.1038/nm1401. View

12.

Gunthorpe M, Benham C, Randall A, Davis J . The diversity in the vanilloid (TRPV) receptor family of ion channels. Trends Pharmacol Sci. 2002; 23(4):183-91. DOI: 10.1016/s0165-6147(02)01999-5. View

13.

Casanova M, Larcher F, Casanova B, Murillas R, Fernandez-Acenero M, Villanueva C . A critical role for ras-mediated, epidermal growth factor receptor-dependent angiogenesis in mouse skin carcinogenesis. Cancer Res. 2002; 62(12):3402-7. View

14.

Biro T, Maurer M, Modarres S, Lewin N, Brodie C, Acs G . Characterization of functional vanilloid receptors expressed by mast cells. Blood. 1998; 91(4):1332-40. View

15.

Inoue K, Koizumi S, Fuziwara S, Denda S, Inoue K, Denda M . Functional vanilloid receptors in cultured normal human epidermal keratinocytes. Biochem Biophys Res Commun. 2002; 291(1):124-9. DOI: 10.1006/bbrc.2002.6393. View

16.

Tsavaler L, Shapero M, Morkowski S, Laus R . Trp-p8, a novel prostate-specific gene, is up-regulated in prostate cancer and other malignancies and shares high homology with transient receptor potential calcium channel proteins. Cancer Res. 2001; 61(9):3760-9. View

17.

Ciardiello F, Tortora G . Epidermal growth factor receptor (EGFR) as a target in cancer therapy: understanding the role of receptor expression and other molecular determinants that could influence the response to anti-EGFR drugs. Eur J Cancer. 2003; 39(10):1348-54. DOI: 10.1016/s0959-8049(03)00235-1. View

18.

Wissenbach U, Niemeyer B, Fixemer T, Schneidewind A, Trost C, Cavalie A . Expression of CaT-like, a novel calcium-selective channel, correlates with the malignancy of prostate cancer. J Biol Chem. 2001; 276(22):19461-8. DOI: 10.1074/jbc.M009895200. View

19.

Sibilia M, Fleischmann A, Behrens A, Stingl L, Carroll J, Watt F . The EGF receptor provides an essential survival signal for SOS-dependent skin tumor development. Cell. 2000; 102(2):211-20. DOI: 10.1016/s0092-8674(00)00026-x. View

20.

Bodo E, Biro T, Telek A, Czifra G, Griger Z, Toth B . A hot new twist to hair biology: involvement of vanilloid receptor-1 (VR1/TRPV1) signaling in human hair growth control. Am J Pathol. 2005; 166(4):985-98. PMC: 1602392. DOI: 10.1016/S0002-9440(10)62320-6. View